Company / PP&E (Net)
Organon & Co. PP&E (Net) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$1.3B
FY2025
5-year range
$973.0M / $1.3B
FY2021-FY2025
Trend
+11.6%
vs FY2024
Sector context
#16 of 193
Health Care
What the data says
Among 193 Health Care companies, Organon & Co. is in the top 8% for pp&e (net). PP&E (Net) has fluctuated over the past 6 years, ranging from $973M in FY2021 to $1.3B in FY2025.
Based on SEC 10-K filings.
$1.3B in FY2025 with a 5-year CAGR of +5.8%. Top quartile in the Health Care sector.
Improved from $1.2B to $1.3B over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +8.6%
- 5-Year CAGR
- +5.8%
- 10-Year CAGR
- -
Sector benchmark
Top 8% in Health CareTop 8% of 193This company $1.3B Sector average $777.6M
▼
+67.6% above sector average
Key checks
Key Insights
- 5-year CAGR of +5.8%, indicating consistent growth.
- In FY2025, pp&e (net) increased 11.6% year-over-year.
- Ranks #16 out of 193 companies in the Health Care sector.
- Lowest pp&e (net) in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score 0.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 55.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.3B | +11.6% |
| FY2024 | $1.2B | -1.3% |
| FY2023 | $1.2B | +16.2% |
| FY2022 | $1.0B | +4.6% |
| FY2021 | $973.0M | -1.1% |
| FY2020 | $984.0M | - |
| FY2019 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026